Patient Anxiety About Prostate Cancer Independently Predicts Early Initiation of Androgen Deprivation Therapy for Biochemical Cancer Recurrence in Older Men: A Prospective Cohort Study

被引:45
作者
Dale, William [1 ]
Hemmerich, Joshua
Bylow, Kathryn
Mohile, Supriya
Mullaney, Mary
Stadler, Walter M.
机构
[1] Univ Chicago, Dept Med, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA
关键词
QUALITY-OF-LIFE; HORMONAL MANAGEMENT; AMERICAN-SOCIETY; HOSPITAL ANXIETY; SCALE; VALIDITY; RISK; RECOMMENDATIONS; SUPPRESSION; MORTALITY;
D O I
10.1200/JCO.2008.18.5850
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Androgen deprivation therapy (ADT) is first-line therapy for patients with prostate cancer (PCA) who experience biochemical recurrence (BCR). However, the optimal timing of ADT initiation is uncertain, and earlier ADT initiation can cause toxicities that lower quality of life (QOL). We tested the hypothesis that elevated cancer anxiety leads to earlier ADT initiation for BCR in older men. Patients and Methods We conducted a prospective cohort study of older patients with BCR of PCA (n = 67). Patients completed questionnaires at presentation and each follow-up visit until initiation of ADT. PCA-specific anxiety was measured with the Memorial Anxiety Scale for Prostate Cancer (MAX-PC). Other collected data included demographics, clinical information, and general anxiety information. Treating oncologists were surveyed about their recommendations for ADT initiation. The primary outcome was the time to ADT initiation. Univariate, multivariate logistic regression, and time-to-event analyses were conducted to evaluate whether cancer anxiety was a predictor of earlier initiation of ADT. Results Thirty-three percent of patients initiated ADT at the first or second clinic visit. Elevated PCA anxiety (MAX-PC > 16) was the most robust predictor in multivariate analyses of early initiation (odds ratio [OR], 9.19; P = .01). PSA also independently correlated with early initiation (OR, 1.31; P = .01). PSA did not correlate with MAX-PC. Conclusion Cancer anxiety independently and robustly predicts earlier ADT initiation in older men with BCR. For older patients with PCA, earlier ADT initiation may not change life expectancy and can negatively impact QOL. PCA-specific anxiety is a potential target for a decision-making intervention in this setting.
引用
收藏
页码:1557 / 1563
页数:7
相关论文
共 35 条
  • [21] Lubeck DP, 2001, UROLOGY, V58, P94, DOI 10.1016/S0090-4295(01)01250-X
  • [22] A pilot study of the vulnerable elders survey-13 compared with the Comprehensive Geriatric Assessment for identifying disability in older patients with prostate cancer who receive androgen ablation
    Mohile, Supriya G.
    Bylow, Kathryn
    Dale, William
    Dignam, James
    Martin, Kandis
    Petrylak, Daniel R.
    Stadler, Walter M.
    Rodin, Miriam
    [J]. CANCER, 2007, 109 (04) : 802 - 810
  • [23] Natural history of progression after PSA elevation following radical prostatectomy
    Pound, CR
    Partin, AW
    Eisenberger, MA
    Chan, DW
    Pearson, JD
    Walsh, PC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17): : 1591 - 1597
  • [24] The memorial anxiety scale for prostate cancer - Validation of a new scale to measure anxiety in men with prostate cancer
    Roth, AJ
    Rosenfeld, B
    Kornblith, AB
    Gibson, C
    Scher, HI
    Curley-Smart, T
    Holland, JC
    Breitbart, W
    [J]. CANCER, 2003, 97 (11) : 2910 - 2918
  • [25] Assessing anxiety in men with prostate cancer: Further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)
    Roth, Andrew
    Nelson, Christian J.
    Rosenfeld, Barry
    Warshowski, Adam
    O'Shea, Noelle
    Scher, Howard
    Holland, Jimmie C.
    Slovin, Susan
    Curley-Smart, Tracy
    Reynolds, Thomas
    Breitbart, William
    [J]. PSYCHOSOMATICS, 2006, 47 (04) : 340 - 347
  • [26] High risk biochemical relapse and the timing of androgen deprivation therapy
    Ryan, Charles J.
    Small, Eric J.
    [J]. JOURNAL OF UROLOGY, 2006, 176 (06) : S61 - S65
  • [27] Quality of life and satisfaction with outcome among prostate-cancer survivors
    Sanda, Martin G.
    Dunn, Rodney L.
    Michalski, Jeff
    Sandler, Howard M.
    Northouse, Laurel
    Hembroff, Larry
    Lin, Xihong
    Greenfield, Thomas K.
    Litwin, Mark S.
    Saigal, Christopher S.
    Mahadevan, Arul
    Klein, Eric
    Kibel, Adam
    Pisters, Louis L.
    Kuban, Deborah
    Kaplan, Irving
    Wood, David
    Ciezki, Jay
    Shah, Nikhil
    Wei, John T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (12) : 1250 - 1261
  • [28] Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist
    Shahinian, Vahakn B.
    Kuo, Yong-Fang
    Freeman, Jean L.
    Goodwin, James S.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (12): : 839 - 845
  • [29] Smith Matthew R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P247, DOI 10.1097/MED.0b013e32814db88c
  • [30] Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer
    Smith, MR
    [J]. CANCER AND METASTASIS REVIEWS, 2002, 21 (02) : 159 - 166